Can low vitamin D weaken immune tolerance and relate to Hashimoto thyroiditis?

Vitamin D acts as a crucial immunomodulatory hormone, and its deficiency is closely linked to a breakdown in self-tolerance and the pathogenesis of autoimmune thyroid disorders.

Mechanistic pathways of immune tolerance

• Treg differentiation and stabilization: Active vitamin D (calcitriol) binds directly to the vitamin D receptor (VDR) on CD4+ T-cells, upregulating FoxP3 expression and reducing DNA methylation at the FOXP3 locus to epigenetically stabilize regulatory T-cell (Treg) identity.
• Dendritic cell programming: Calcitriol programs dendritic cells into a tolerogenic phenotype characterized by low costimulatory molecule expression and high IL-10 production, which preferentially expands FoxP3+ and IL-10+ Tregs.
• Loss of immune suppression: Insufficient vitamin D disrupts these VDR-mediated pathways, impairing Treg frequency and activity. This shifts the immunological balance toward autoreactive Th1 and Th17 effector T-cells, weakening overall peripheral immune tolerance.

Clinical evidence in autoimmune thyroiditis

• Disease association and progression: Observational and case-control studies show that patients with Hashimoto's thyroiditis have significantly lower circulating 25-hydroxyvitamin D [25(OH)D] levels. Lower levels correlate with higher thyroid-stimulating hormone (TSH) levels and a greater risk of progressing from subclinical to overt hypothyroidism.
• Reduction of thyroid autoantibodies: Vitamin D deficiency is consistently linked to elevated anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) autoantibodies. Meta-analyses demonstrate that correcting this deficiency via vitamin D3 supplementation for three months or longer significantly reduces these antibody titers, particularly in baseline-deficient patients.

Bottom line

• Vitamin D deficiency directly impairs the molecular pathways that maintain peripheral immune tolerance, predisposing individuals to Hashimoto's thyroiditis and elevated thyroid autoantibodies, which can be clinically improved through targeted vitamin D3 supplementation.